NDA 050588 · Pai Holdings Pharm
Cefotan
Cefotetan Disodium · Injection
NovelLast checked: Nov 19, 2026Latest source record: Mar 9, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1985
Dec 27, 1985
Approved uses
2
Original approval plus efficacy supplements
Registered trials
6
1 Phase 3, 1 recruiting
FAERS reports
133
109 serious, 17 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 8, 2024.
INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of CEFOTAN ® and other antibacterial drugs, CEFOTAN ® should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment CEFOTAN® (Cefotetan for Injection, USP) is indicated for the therapeutic treatment of the following infections when caused by susceptible strains of the designated organisms: Urinary Tract Infections caused by E. coli , Klebsiella spp (including K. pneumoniae ), Proteus mirabilis , Proteus vulgaris , Providencia rettgeri , and Morganella morganii . Lower Respiratory Tract Infections caused by Streptococcus pneumoniae , Staphylococcus aureus (methicillin susceptible), Haemophilus influenza e, Klebsiella species (including K. pneumoniae ), E. coli , Proteus mirabilis , and Serratia marcescens .* Skin and Skin Structure Infections due to Staphylococcus aureus (methicillin-susceptible), Staphylococcus epidermidis (methicillin susceptible), Streptococcus pyogenes , Streptococcus species, Escherichia coli , Klebsiella pneumoniae , Peptococcus niger *, Peptostreptococcus species. Gynecologic Infections caused by Staphylococcus aureus (methicillin susceptible), Staphylococcus epidermidis (methicillin susceptible, Streptococcus species, Streptococcus agalactiae , E. coli , Proteus mirabilis , Neisseria gonorrhoeae , Bacteroides fragilis , Prevotella melaninogenica Bacteroides vulgatus , Fusobacterium species*, and gram-positive...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 25, 1991 Supplement 2 · Efficacy
- Dec 27, 1985 Original approval · Type 1 - New Molecular Entity Review
3 products under this application
- CEFOTAN · CEFOTETAN DISODIUM EQ 2GM BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
- CEFOTAN · CEFOTETAN DISODIUM EQ 10GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
- CEFOTAN · CEFOTETAN DISODIUM EQ 1GM BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Cefotetan Disodium" as an intervention, any sponsor and status, largest first.
- A Single Dose of a Marketed Drug Being Studied for a New Indication to Treat Surgical Site Infection Following Colorectal Surgery as Compared to a Marketed Drug Approved for This Indication (0826-039)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00090272 · 952 participants · Start Apr 2002 · Primary completion Mar 2005
Drug: MK0826, ertapenem sodium; Comparator: cefotetan · For: Colorectal Surgery
- Effectiveness of Prophylactic Antibiotics Therapy in Laparoscopic Cholecystectomy on Infection RatePivotal-lookingCompleted
Chonbuk National University HospitalAcademic, hospital or other
NCT04726046 · 529 participants · Start Apr 1, 2014 · Primary completion Aug 1, 2015
Drug: Cefotetan · For: Cholecystitis
National Cancer Center, KoreaGovernment (non-federal)
NCT01220661 · 312 participants · Start Oct 2010 · Primary completion Dec 2011
Drug: Cefotetan · For: Colorectal Surgery
Sites: Goyang-si, South Korea
- Antibiotics for Postpartum Third and Fourth Degree Perineal Tear RepairsPivotal-lookingCompleted
Stanford UniversityAcademic, hospital or other
NCT00186082 · 147 participants · Start Sep 2003 · Primary completion Jun 2006
Drug: Cefotetan or Cefoxitin vs placebo · For: Pregnancy Complications, Infectious
Sites: San Jose, California; Stanford, California
Oregon Health and Science UniversityAcademic, hospital or other
NCT07318584 · 50 participants (planned) · Start Jun 26, 2026 · Primary completion Oct 2028
Drug: Cefotetan; Carbapenems and 1 more · For: E Coli Infection; ESBL Producing E.Coli
Sites: Portland, Oregon
Julio RamirezAcademic, hospital or other
NCT02099240 · 11 participants · Start Mar 6, 2014 · Primary completion Nov 7, 2018
Drug: oral antibiotics · For: Osteomyelitis
Sites: Louisville, Kentucky
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- haemolytic anaemia20
- nausea9
- renal failure9
- asthenia8
- chronic kidney disease8
- anaemia7
- dizziness7
- dyspnoea7
- hypertension7
- pain7
- urticaria7
- abdominal pain6
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 15 |
| 2005 | 8 |
| 2006 | 13 |
| 2007 | 3 |
| 2008 | 9 |
| 2009 | 8 |
| 2010 | 7 |
| 2011 | 9 |
| 2012 | 8 |
| 2013 | 3 |
| 2014 | 2 |
| 2015 | 9 |
| 2016 | 3 |
| 2017 | 4 |
| 2018 | 4 |
| 2019 | 4 |
| 2020 | 4 |
| 2021 | 6 |
| 2022 | 4 |
| 2023 | 8 |
| 2024 | 1 |
| 2025 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Cefotetan disodium (Cefotan).
· Med Lett Drugs Ther 1986 · Clinical Trial
- Pharmacokinetics and tolerance of single intravenous doses of cefotetan disodium in male Caucasian volunteers.
Yates RA, Adam HK, Donnelly RJ, et al. · J Antimicrob Chemother 1983 · Clinical Trial, Randomized Controlled Trial
- Prophylactic antibiotics for elective laparoscopic cholecystectomy: are they necessary?
Higgins A, London J, Charland S, et al. · Arch Surg 1999 · Clinical Trial, Randomized Controlled Trial
- Cefotetan (Cefotan): a new cephalosporin.
Ahmed ME, May G, Branch RA · Ration Drug Ther 1986 · Clinical Trial, Research Support, Non-U.S. Gov't
- Pharmacokinetics and Tolerability of Single and Multiple Intravenous Doses of Cefotetan Disodium in Healthy Chinese Volunteers.
Liu J, Zhai Y, Wu L, et al. · Drug Des Devel Ther 2020 · Comparative Study, Randomized Controlled Trial
- Absolute bioavailability and noncompartmental analysis of intravenous and intramuscular Cefotan (cefotetan) in normal volunteers.
Zimmerman J, Cohen A, Thyrum P · J Clin Pharmacol 1989 · Clinical Trial, Controlled Clinical Trial
Sponsor: Pai Holdings Pharm
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.